1022091-49-1Relevant articles and documents
Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization
Zhao, Fei,Zhang, Le-Duo,Hao, Yu,Chen, Na,Bai, Rui,Wang, Yu-Ji,Zhang, Chun-Chun,Li, Gong-Sheng,Hao, Li-Jun,Shi, Chen,Zhang, Jing,Mao, Yu,Fan, Yi,Xia, Guang-Xin,Yu, Jian-Xin,Liu, Yan-Jun
supporting information, p. 147 - 158 (2017/04/17)
c-Met/HGF signaling pathway plays an important role in cancer progression, and it was considered to be related to poor prognosis and drug resistance. Based on metabolite profiling of (S)-7-fluoro-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyrazin
HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION
-
, (2011/02/24)
The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
HETEROCYCLIC KINASE MODULATORS
-
Page/Page column 108, (2009/01/20)
The present disclosure provides heterocyclic protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.